All news

Big Pharma China deal spree grows with $7.8 billion tie-up

CNBC · RSS · · AI-summarised by FinFlash

Western biopharma companies are increasingly turning to China to source innovation, with the latest tie-up valued at up to $7.8 billion. The deal spree comes as the industry braces for pharma's dreaded "patent cliff," a wave of expiring drug patents expected to erode revenue. Licensing and partnership agreements with Chinese drugmakers have become a key route for large pharmaceutical firms seeking to replenish pipelines ahead of those losses.

Read original source

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.